Clinical Trials Browser

Phase 3 × Has results × Gemcitabine × Clear all

NCT04924062 2026-04-15

KEYNOTE-966

Phase 3 Completed

158 enrolled 19 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT04003636 2026-03-24

KEYNOTE-966

Phase 3 Completed

1,069 enrolled 19 charts 2 FDA

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT03164616 2026-03-13

POSEIDON

Phase 3 Active not recruiting

1,186 enrolled 26 charts 2 FDA

Non Small Cell Lung Cancer NSCLC

NCT03732677 2026-03-13

NIAGARA

Phase 3 Active not recruiting

1,063 enrolled 15 charts 3 FDA

Urinary Bladder Neoplasms

NCT03003962 2026-03-11

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

Phase 3 Active not recruiting

669 enrolled 54 charts

Non Small Cell Lung Carcinoma NSCLC

NCT04083235 2026-03-09

NAPOLI 3

Phase 3 Completed

770 enrolled 13 charts 2 FDA

Gastrointestinal

Metastatic Adenocarcinoma of the Pancreas

NCT03036098 2026-03-06

CheckMate901

Phase 3 Active not recruiting

1,314 enrolled 23 charts 2 FDA

Urothelial Cancer

NCT05171647 2026-03-06

SUNMO

Phase 3 Active not recruiting

208 enrolled 12 charts

Lymphoma, Non-Hodgkin

NCT02446600 2026-03-05

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 3 Active not recruiting

579 enrolled 17 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04222972 2026-03-05

AcceleRET-Lung

Phase 3 Terminated

223 enrolled 18 charts

Head & NeckThoracic

Adenocarcinoma, Bronchial Diseases, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT02453282 2026-03-02

MYSTIC

Phase 3 Active not recruiting

1,118 enrolled 40 charts

Carcinoma, Non-Small-Cell Lung

NCT04697628 2026-02-24

innovaTV 301

Phase 3 Completed

502 enrolled 18 charts 2 FDA

Uterine Cervical Neoplasms

NCT01013649 2026-02-23

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

Phase 3 Completed

546 enrolled 29 charts

Gastrointestinal

Pancreatic Intraductal Neoplasms

NCT02542293 2026-02-12

NEPTUNE

Phase 3 Active not recruiting

953 enrolled 29 charts

Non Small Cell Lung Carcinoma NSCLC

NCT02486718 2026-02-05

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

Phase 3 Active not recruiting

1,280 enrolled 24 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT05104866 2026-02-04

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

Phase 3 Active not recruiting

732 enrolled 22 charts 3 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT03456076 2026-01-30

A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

Phase 3 Active not recruiting

257 enrolled 14 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT02516241 2026-01-28

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

Phase 3 Active not recruiting

1,126 enrolled 52 charts

Urothelial Cancer

NCT03377491 2026-01-21

Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)

Phase 3 Completed

571 enrolled 22 charts

Gastrointestinal

Pancreas Adenocarcinoma

NCT03768414 2026-01-12

Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

Phase 3 Completed

452 enrolled 17 charts

Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma

NCT02998528 2026-01-06

CheckMate 816

Phase 3 Completed

505 enrolled 17 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Phase 3 Active not recruiting

1,052 enrolled 27 charts

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

NCT04182204 2025-12-22

POLARGO

Phase 3 Completed

270 enrolled 36 charts

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT03371017 2025-11-12

IMpassion132

Phase 3 Completed

595 enrolled 37 charts

Triple Negative Breast Neoplasms

NCT02477826 2025-10-30

CheckMate 227

Phase 3 Completed

2,747 enrolled 21 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT03734029 2025-10-06

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Phase 3 Active not recruiting

557 enrolled 22 charts 2 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT04458909 2025-10-03

Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer

Phase 3 Terminated

15 enrolled 17 charts

Nasopharyngeal Carcinoma

NCT05092360 2025-08-28

ARTISTRY-7

Phase 3 Terminated

456 enrolled 19 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00981058 2025-06-18

SQUIRE

Phase 3 Completed

1,093 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung

NCT04223856 2025-06-13

EV-302

Phase 3 Active not recruiting

886 enrolled 12 charts 2 FDA

Urothelial Cancer

NCT03710876 2025-05-20

INFINITE

Phase 3 Active not recruiting

53 enrolled 23 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT01746979 2025-05-11

MAESTRO

Phase 3 Completed

693 enrolled 8 charts

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms

NCT00446225 2025-03-05

EURTAC

Phase 3 Completed

174 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT00324805 2025-03-03

Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

Phase 3 Completed

1,501 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT02807636 2025-02-24

IMvigor130

Phase 3 Completed

1,213 enrolled 35 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02576574 2025-01-31

Avelumab in First-line NSCLC (JAVELIN Lung 100)

Phase 3 Completed

1,214 enrolled 40 charts

Carcinoma, Non-Small-Cell Lung

NCT03924986 2025-01-31

RATIONALE-309

Phase 3 Completed

263 enrolled 19 charts

Nasopharyngeal Neoplasms, Recurrence

NCT00478699 2024-12-12

GECP-SCAT

Phase 3 Completed

500 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung

NCT03425643 2024-12-03

MK-3475-671

Phase 3 Active not recruiting

797 enrolled 23 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT02819518 2024-11-27

KEYNOTE-355

Phase 3 Completed

882 enrolled 41 charts 3 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT03941093 2024-11-05

LAPIS

Phase 3 Completed

284 enrolled 14 charts

Gastrointestinal

Pancreatic Cancer Non-resectable

NCT03191786 2024-10-23

IPSOS

Phase 3 Completed

453 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung

NCT03901339 2024-10-21

TROPiCS-02

Phase 3 Completed

543 enrolled 25 charts 2 FDA

Breast Neoplasms

NCT02352948 2024-07-26

ARCTIC

Phase 3 Completed

597 enrolled 23 charts

Non - Small Cell Lung Cancer NSCLC

NCT01231347 2024-07-16

GAMMA

Phase 3 Completed

800 enrolled 11 charts

Gastrointestinal

Endocrine Gland Neoplasms, Jaundice, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT03703375 2024-07-08

Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma

Phase 3 Active not recruiting

93 enrolled 19 charts

Lymphoma, Lymphoma, T-Cell

NCT02049905 2024-06-13

Phase 3 Study to Treat Patients With Soft Tissue Sarcomas

Phase 3 Completed

433 enrolled 10 charts

Neoplasm Metastasis, Sarcoma

NCT03773302 2024-05-08

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

Phase 3 Terminated

48 enrolled 26 charts

Gastrointestinal

Cholangiocarcinoma

NCT05493501 2024-05-02

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

Phase 3 Terminated

8 enrolled 7 charts

NSCLC

NCT02395016 2024-04-04

A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer

Phase 3 Completed

90 enrolled 18 charts

Gastrointestinal

Pancreatic Neoplasms